Pathogenesis of liver fibrosis

Annual Review of Pathology: Mechanisms of Disease

Volumn 6, Issue , 2011, Pages 425-456

  Hernandez Gea, Virginia ^a   Friedman, Scott L ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

cirrhosis; extracellular matrix; hepatic stellate cells; myofibroblasts

Indexed keywords

2 [1 CARBOXY 2 [4 [2 (5 METHYL 2 PHENYL 4 OXAZOLYL)ETHOXY]PHENYL]ETHYLAMINO]BENZOIC ACID METHYL ESTER; ADAM PROTEIN; ADIPOCYTOKINE; ALPHA INTERFERON; CONNECTIVE TISSUE GROWTH FACTOR; DISCOIDIN DOMAIN RECEPTOR 2; ENDOCANNABINOID; GAMMA INTERFERON; GROWTH FACTOR; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; LEPTIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PLASMINOGEN; PLATELET DERIVED GROWTH FACTOR; PROTEIN ADAMSTS 1; PROTEIN ADAMSTS 13; RANTES; STAT1 PROTEIN; STAT2 PROTEIN; STEM CELL FACTOR; THROMBIN; TRANSFORMING GROWTH FACTOR; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ARTICLE; CELL ACTIVATION; CHRONIC LIVER DISEASE; CYTOKINE PRODUCTION; EPIGENETICS; EXTRACELLULAR MATRIX; FIBROGENESIS; GENE EXPRESSION REGULATION; GENETIC REGULATION; HUMAN; LIVER FIBROSIS; MORBIDITY; MORTALITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

HUMANS; LIVER; LIVER CIRRHOSIS; SIGNAL TRANSDUCTION;

EID: 79751506514     PISSN: 15534006     EISSN: 15534014     Source Type: Book Series    
DOI: 10.1146/annurev-pathol-011110-130246     Document Type: Article

References (217)

1. Schaffner F, Popper H. 1963. Capillarization of hepatic sinusoids in man. Gastroenterology 44:239-42
2. Cassiman D, Libbrecht L, Desmet V, Denef C, Roskams T. 2002. Hepatic stellate cell/myofibroblast subpopulations in fibrotic human and rat livers. J. Hepatol. 36:200-9 (Pubitemid 34146426)
3. Fernandez M, Semela D, Bruix J, Colle I, Pinzani M, Bosch J. 2009. Angiogenesis in liver disease. J. Hepatol. 50:604-20
4. El-Serag HB, Rudolph KL. 2007. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132:2557-76 (Pubitemid 46890874)
5. Schuppan D, Ruehl M, Somasundaram R, Hahn EG. 2001. Matrix as modulator of stellate cell and hepatic fibrogenesis. Semin. Liver Dis. 21:351-72 (Pubitemid 32923765)
6. Geerts A. 2001. History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells. Semin. Liver Dis. 21:311-35 (Pubitemid 32923763)
7. Olaso E, Ikeda K, Eng FJ, Xu L, Wang LH, et al. 2001. DDR2 receptor promotes MMP-2-mediated proliferation and invasion by hepatic stellate cells. J. Clin. Investig. 108:1369-78 (Pubitemid 33107765)
8. Gressner AM. 1995. Cytokines and cellular crosstalk involved in the activation of fat-storing cells. J. Hepatol. 22:28-36
9. SchuppanD, Ruehl M, Somasundaram R, Hahn EG. 2001. Matrix as amodulator of hepatic fibrogenesis. Semin. Liver Dis. 21:351-72
10. Avraamides CJ, Garmy-Susini B, Varner JA. 2008. Integrins in angiogenesis and lymphangiogenesis. Nat. Rev. Cancer 8:604-17
11. Stupack DG. 2007. The biology of integrins. Oncology 21:6-12
12. Friedman SL. 2008. Hepatic stellate cells-protean, multifunctional, and enigmatic cells of the liver. Physiol. Rev. 88:125-72
13. Popov Y, Patsenker E, Stickel F, Zaks J, Bhaskar KR, et al. 2008. Integrin ávâ6 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies. J. Hepatol. 48:453-64
14. Hehlgans S, Haase M, Cordes N. 2007. Signaling via integrins: implications for cell survival and anticancer strategies. Biochim. Biophys. Acta 1775:163-80 (Pubitemid 44881199)
15. Omenetti A, Porrello A, Jung Y, Yang L, Popov Y, et al. 2008. Hedgehog signaling regulates epithelialmesenchymal transition during biliary fibrosis in rodents and humans. J. Clin. Investig. 118:3331-42
16. Omenetti A, Popov Y, Jung Y, Choi SS, Witek RP, et al. 2008. The hedgehog pathway regulates remodelling responses to biliary obstruction in rats. Gut 57:1275-82
17. Kesteloot F, Desmouliere A, Leclercq I, Thiry M, Arrese JE, et al. 2007. ADAM metallopeptidase with thrombospondin type 1 motif 2 inactivation reduces the extent and stability of carbon tetrachloride- induced hepatic fibrosis in mice. Hepatology 46:1620-31 (Pubitemid 350155543)
18. NiiyaM, UemuraM, Zheng XW, Pollak ES, DockalM, et al. 2006. Increased ADAMTS-13 proteolytic activity in rat hepatic stellate cells upon activation in vitro and in vivo. J. Thromb. Haemost. 4:1063-70
19. Olaso E, Labrador JP, Wang L, Ikeda K, Eng FJ, et al. 2002. Discoidin domain receptor 2 regulates fibroblast proliferation and migration through the extracellular matrix in association with transcriptional activation of matrix metalloproteinase 2. J. Biol. Chem. 277:3606-13 (Pubitemid 34953233)
20. Ikeda K,Wang LH, Torres R, Zhao H, Olaso E, et al. 2002. Discoidin domain receptor 2 interacts with Src and Shc following its activation by type I collagen. J. Biol. Chem. 277:19206-12 (Pubitemid 34952488)
21. Labrador JP, Azcoitia V, Tuckermann J, Lin C, Olaso E, et al. 2001. The collagen receptor DDR2 regulates proliferation and its elimination leads to dwarfism. EMBO Rep. 2:446-52 (Pubitemid 32519565)
22. Mao TK, Kimura Y, Kenny TP, Branchi A, Gishi RG, et al. 2002. Elevated expression of tyrosine kinase DDR2 in primary biliary cirrhosis. Autoimmunity 35:521-29 (Pubitemid 36321893)
23. Friedman SL. 2010. Evolving challenges in hepatic fibrosis. Nat. Rev. Gastroenterol. Hepatol. 7:425-36
24. Reynaert H, Thompson MG, Thomas T, Geerts A. 2002. Hepatic stellate cells: role in microcirculation and pathophysiology of portal hypertension. Gut 50:571-81 (Pubitemid 34638880)
25. Friedman SL. 2008. Mechanisms of hepatic fibrogenesis. Gastroenterology 134:1655-69 (Pubitemid 351615417)
26. Kalluri R, Zeisberg M. 2006. Fibroblasts in cancer. Nat. Rev. Cancer 6:392-401
27. Novo E, di Bonzo LV, Cannito S, Colombatto S, Parola M. 2009. Hepatic myofibroblasts: a heterogeneous population of multifunctional cells in liver fibrogenesis. Int. J. Biochem. Cell Biol. 41:2089-93
28. Parola M, Marra F, PinzaniM. 2008. Myofibroblast-like cells and liver fibrogenesis: emerging concepts in a rapidly moving scenario. Mol. Aspects Med. 29:58-66 (Pubitemid 351312216)
29. Soliman EM, Rodrigues MA, Gomes DA, Sheung N, Yu J, et al. 2009. Intracellular calcium signals regulate growth of hepatic stellate cells via specific effects on cell cycle progression. Cell Calcium 45:284-92
30. Baertschiger RM, Serre-Beinier V, Morel P, Bosco D, Peyrou M, et al. 2009. Fibrogenic potential of human multipotent mesenchymal stromal cells in injured liver. PLoS One 4:e6657
31. Russo FP, Alison MR, Bigger BW, Amofah E, Florou A, et al. 2006. The bone marrow functionally contributes to liver fibrosis. Gastroenterology 130:1807-21 (Pubitemid 43668827)
32. Forbes SJ, Russo FP, Rey V, Burra P, Rugge M, et al. 2004. A significant proportion of myofibroblasts are of bone marrow origin in human liver fibrosis. Gastroenterology 126:955-63 (Pubitemid 38451166)
33. Fujimiya T, Liu J, Kojima H, Shirafuji S, Kimura H, Fujimiya M. 2009. Pathological roles of bone marrow-derived stellate cells in amousemodel of alcohol-induced fatty liver. Am. J. Physiol. Gastrointest. Liver Physiol. 297:G451-60
34. Higashiyama R, Moro T, Nakao S, Mikami K, Fukumitsu H, et al. 2009. Negligible contribution of bone marrow-derived cells to collagen production during hepatic fibrogenesis in mice. Gastroenterology 137:1459-66 e1
35. Choi SS, Diehl AM. 2009. Epithelial-to-mesenchymal transitions in the liver. Hepatology 50:2007-13
36. Kalluri R, Neilson EG. 2003. Epithelial-mesenchymal transition and its implications for fibrosis. J. Clin. Investig. 112:1776-84 (Pubitemid 38063698)
37. Okada H, Strutz F, Danoff TM, Kalluri R, Neilson EG. 1996. Possible mechanisms of renal fibrosis. Contrib. Nephrol. 118:147-54
38. Lee JM, Dedhar S, Kalluri R, ThompsonEW.2006. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J. Cell Biol. 172:973-81
39. Zeisberg M, Hanai J, Sugimoto H, Mammoto T, Charytan D, et al. 2003. BMP-7 counteracts TGF- â1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat. Med. 9:964-68 (Pubitemid 36889942)
40. Kalluri R, Weinberg RA. 2009. The basics of epithelial-mesenchymal transition. J. Clin. Investig. 119:1420-28
41. Zavadil J, Bottinger EP. 2005. TGF-âand epithelial-to-mesenchymal transitions. Oncogene 24:5764-74
42. Choi SS, Omenetti A, Witek RP, Moylan CA, Syn WK, et al. 2009. Hedgehog pathway activation and epithelial-to-mesenchymal transitions during myofibroblastic transformation of rat hepatic cells in culture and cirrhosis. Am. J. Physiol. Gastrointest. Liver Physiol. 297:G1093-106
43. Xia JL, Dai C, Michalopoulos GK, Liu Y. 2006. Hepatocyte growth factor attenuates liver fibrosis induced by bile duct ligation. Am. J. Pathol. 168:1500-12
44. Diaz R, Kim JW, Hui JJ, Li Z, Swain GP, et al. 2008. Evidence for the epithelial to mesenchymal transition in biliary atresia fibrosis. Hum. Pathol. 39:102-15 (Pubitemid 350216166)
45. Rygiel KA, RobertsonH,Marshall HL, Pekalski M, Zhao L, et al. 2008. Epithelial-mesenchymal transition contributes to portal tract fibrogenesis during human chronic liver disease. Lab. Investig. 88:112-23 (Pubitemid 351161272)
46. Kaimori A, Potter J, Kaimori JY, Wang C, Mezey E, Koteish A. 2007. Transforming growth factor â1 induces an epithelial-to-mesenchymal transition state in mouse hepatocytes in vitro. J. Biol. Chem. 282:22089-101 (Pubitemid 47195788)
47. Zeisberg M, Yang C, Martino M, Duncan MB, Rieder F, et al. 2007. Fibroblasts derive from hepatocytes in liver fibrosis via epithelial tomesenchymal transition. J. Biol. Chem. 282:23337-47 (Pubitemid 47311952)
48. Taura K, Miura K, Iwaisako K, Osterreicher CH, Kodama Y, et al. 2009. Hepatocytes do not undergo epithelial-mesenchymal transition in liver fibrosis in mice. Hepatology 51:1027-36
49. Wells RG. 2010. The epithelial-to-mesenchymal transition in liver fibrosis: here today, gone tomorrow? Hepatology 51:737-40
50. Potenta S, Zeisberg E, Kalluri R. 2008. The role of endothelial-to- mesenchymal transition in cancer progression. Br. J. Cancer 99:1375-79
51. Zeisberg EM, Tarnavski O, Zeisberg M, Dorfman AL, McMullen JR, et al. 2007. Endothelial-tomesenchymal transition contributes to cardiac fibrosis. Nat. Med. 13:952-61 (Pubitemid 47222040)
52. Marra F, Bertolani C. 2009. Adipokines in liver diseases. Hepatology 50:957-69
53. Marra F. 2007. Leptin and liver tissue repair:Do rodent models provide the answers? J. Hepatol. 46:12-18 (Pubitemid 44834430)
54. Ikejima K, Takei Y, Honda H,HiroseM, Yoshikawa M, et al. 2002. Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology 122:1399-410 (Pubitemid 34465182)
55. Saxena NK, Sharma D, Ding X, Lin S, Marra F, et al. 2007. Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res. 67:2497-507 (Pubitemid 46548934)
56. Fava G, Alpini G, Rychlicki C, Saccomanno S, DeMorrow S, et al. 2008. Leptin enhances cholangiocarcinoma cell growth. Cancer Res. 68:6752-61
57. Marra F. 2002. Leptin and liver fibrosis: a matter of fat. Gastroenterology 122:1529-32 (Pubitemid 34465194)
58. Ding X, Saxena NK, Lin S, Xu A, Srinivasan S, Anania FA. 2005. The roles of leptin and adiponectin: a novel paradigm in adipocytokine regulation of liver fibrosis and stellate cell biology. Am. J. Pathol. 166:1655-69 (Pubitemid 40734389)
59. Moreno M, Bataller R. 2008. Cytokines and renin-angiotensin system signaling in hepatic fibrosis. Clin. Liver Dis. 12:825-52
60. Pinzani M, Gesualdo L, Sabbah GM, Abboud HE. 1989. Effects of platelet-derived growth factor and other polypeptide mitogens on DNA synthesis and growth of cultured rat liver fat-storing cells. J. Clin. Investig. 84:1786-93 (Pubitemid 20016182)
61. Borkham-Kamphorst E, van Roeyen CR, Ostendorf T, Floege J, Gressner AM, Weiskirchen R. 2007. Pro-fibrogenic potential of PDGF-D in liver fibrosis. J. Hepatol. 46:1064-74 (Pubitemid 46669736)
62. Pinzani M, Milani S, Herbst H, DeFranco R, Grappone C, et al. 1996. Expression of platelet-derived growth factor and its receptors in normal human liver and during active hepatic fibrogenesis. Am. J. Pathol. 148:785-800 (Pubitemid 126660671)
63. Wong L, Yamasaki G, Johnson RJ, Friedman SL. 1994. Induction of â-platelet-derived growth factor receptor in rat hepatic lipocytes during cellular activation in vivo and in culture. J. Clin. Investig. 94:1563-69
64. Inagaki Y, Okazaki I. 2007. Emerging insights into TGFâand Smad signaling in hepatic fibrogenesis. Gut 56:284-92
65. Novo E, Cannito S, Zamara E, Valfre di Bonzo L, Caligiuri A, et al. 2007. Proangiogenic cytokines as hypoxia-dependent factors stimulatingmigration of human hepatic stellate cells.Am. J. Pathol. 170:1942-53 (Pubitemid 47339268)
66. Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, et al. 2003. Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis. Gut 52:1347-54 (Pubitemid 37026470)
67. Yu C, Wang F, Jin C, Huang X, Miller DL, et al. 2003. Role of fibroblast growth factor type 1 and 2 in carbon tetrachloride-induced hepatic injury and fibrogenesis. Am. J. Pathol. 163:1653-62 . (Pubitemid 37175112)
68. CanturkNZ, CanturkZ,Ozden M, Dalcik H, YardimogluM,Tulubas F. 2003. Protective effect of IGF-1 on experimental liver cirrhosis-induced common bile duct ligation. Hepatogastroenterology 50:2061-66 (Pubitemid 37467995)
69. Sanz S, Pucilowska JB, Liu S, Rodriguez-Ortigosa CM, Lund PK, et al. 2005. Expression of insulin-like growth factor I by activated hepatic stellate cells reduces fibrogenesis and enhances regeneration after liver injury. Gut 54:134-41 (Pubitemid 40007233)
70. Reichenbach V, Ros J, Jimenez W. 2009. Endogenous cannabinoids in liver disease: many darts for a single target. Gastroenterol. Hepatol. 33:323-29
71. Siegmund SV, Schwabe RF. 2008. Endocannabinoids and liver disease. II. Endocannabinoids in the pathogenesis and treatment of liver fibrosis. Am. J. Physiol. Gastrointest. Liver Physiol. 294:G357-62 (Pubitemid 351253327)
72. Teixeira-Clerc F, Julien B, Grenard P, Tran Van Nhieu J, Deveaux V, et al. 2006. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat. Med. 12:671-76 (Pubitemid 43865236)
73. Julien B, Grenard P, Teixeira-Clerc F, Van Nhieu JT, Li L, et al. 2005. Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology 128:742-55 (Pubitemid 40585376)
74. Sims DE. 1991. Recent advances in pericyte biology-implications for health and disease. Can. J. Cardiol. 7:431-43
75. Feng HQ, Weymouth ND, Rockey DC. 2009. Endothelin antagonism in portal hypertensive mice: implications for endothelin receptor-specific signaling in liver disease. Am. J. Physiol. Gastrointest. Liver Physiol. 297:G27-33
76. Thimgan MS, Yee HF Jr. 1999. Quantitation of rat hepatic stellate cell contraction: stellate cells' contribution to sinusoidal resistance. Am. J. Physiol. 277:G137-43 (Pubitemid 29352654)
77. Shao R, RockeyDC. 2002. Effects of endothelins on hepatic stellate cell synthesis of endothelin-1 during hepatic wound healing. J. Cell Physiol. 191:342-50 (Pubitemid 34462485)
78. Rockey DC. 2001. Cellular pathophysiology of portal hypertension and prospects for management with gene therapy. Clin. Liver Dis. 5:851-65 (Pubitemid 32847063)
79. Shao R, Yan W, Rockey DC. 1999. Regulation of endothelin-1 synthesis by endothelin-converting enzyme-1 during wound healing. J. Biol. Chem. 274:3228-34 (Pubitemid 29075413)
80. Housset C, Rockey DC, Bissell DM. 1993. Endothelin receptors in rat liver: lipocytes as a contractile target for endothelin 1. Proc. Natl. Acad. Sci USA 90:9266-70 (Pubitemid 23315764)
81. Rockey DC. 2003. Vascular mediators in the injured liver. Hepatology 37:4-12 (Pubitemid 36042137)
82. Loureiro-Silva MR, Cadelina GW, Groszmann RJ. 2003. Deficit in nitric oxide production in cirrhotic rat livers is located in the sinusoidal and postsinusoidal areas. Am. J. Physiol. Gastrointest. Liver Physiol. 284:G567-74 (Pubitemid 36343205)
83. Bataller R, Sancho-Bru P, Gines P, Brenner DA. 2005. Liver fibrogenesis: a new role for the reninangiotensin system. Antioxid. Redox Signal. 7:1346-55 (Pubitemid 41232532)
84. Bataller R, Sancho-Bru P, Gines P, Lora JM, Al-Garawi A, et al. 2003. Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology 125:117-25 (Pubitemid 36799113)
85. Bosch J, Arroyo V, Betriu A, Mas A, Carrilho F, et al. 1980. Hepatic hemodynamics and the reninangiotensin- aldosterone system in cirrhosis. Gastroenterology 78:92-99 (Pubitemid 10216855)
86. Oakley F, Teoh V, Ching ASG, Bataller R, Colmenero J, et al. 2009. Angiotensin II activates I kappa B kinase phosphorylation of RelA at Ser 536 to promote myofibroblast survival and liver fibrosis. Gastroenterology 136:2334-44
87. Lubel JS, Herath CB,Tchongue J, Grace J, Jia Z, et al. 2009. Angiotensin-(1-7), an alternative metabolite of the renin-angiotensin system, is up-regulated in human liver disease and has antifibrotic activity in the bile-duct-ligated rat. Clin. Sci. 117:375-86
88. Osterreicher CH, Taura K, De Minicis S, Seki E, Penz-Osterreicher M, et al. 2009. Angiotensinconverting enzyme 2 inhibits liver fibrosis in mice. Hepatology 50:929-38
89. Suematsu M, Goda N, Sano T, Kashiwagi S, Egawa T, et al. 1995. Carbon monoxide: an endogenous modulator of sinusoidal tone in the perfused rat liver. J. Clin. Investig. 96:2431-37
90. Gorbig MN, Gines P, Bataller R, Nicolas JM, Garcia-Ramallo E, et al. 1999. Atrial natriuretic peptide antagonizes endothelin-induced calcium increase and cell contraction in cultured human hepatic stellate cells. Hepatology 30:501-9 (Pubitemid 29357517)
91. Kawada N, KleinH,Decker K. 1992. Eicosanoid-mediated contractility of hepatic stellate cells. Biochem. J. 285:367-71
92. Tao J, Mallat A, Gallois C, Belmadani S, Mery PF, et al. 1999. Biological effects of C-type natriuretic peptide in human myofibroblastic hepatic stellate cells. J. Biol. Chem. 274:23761-69
93. Yanase M, IkedaH,Matsui A,Maekawa H, Noiri E, et al. 2000. Lysophosphatidic acid enhances collagen gel contraction by hepatic stellate cells: association with rho-kinase. Biochem. Biophys. Res. Commun. 277:72-78
94. Ueno T, Tanikawa K. 1997. Intralobular innervation and lipocyte contractility in the liver. Nutrition 13:141-48 (Pubitemid 27172289)
95. Hashmi AZ, Hakim W, Kruglov EA, Watanabe A, Watkins W, et al. 2007. Adenosine inhibits cytosolic calcium signals and chemotaxis in hepatic stellate cells. Am. J. Physiol. Gastrointest. Liver Physiol. 292:G395-401 (Pubitemid 46091633)
96. Lechuga CG, Hernandez-Nazara ZH, Hernandez E, Bustamante M, Desierto G, et al. 2006. PI3K is involved in PDGF-â receptor upregulation post-PDGF-BB treatment in mouse HSC. Am. J. Physiol. Gastrointest. Liver Physiol. 291:G1051-61 (Pubitemid 44904159)
97. Aleffi S, Petrai I, Bertolani C, Parola M, Colombatto S, et al. 2005. Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. Hepatology 42:1339-48 (Pubitemid 43260036)
98. Bataller R, Schwabe RF, Choi YH, Yang L, Paik YH, et al. 2003. NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. J. Clin. Investig. 112:1383-94 (Pubitemid 38057692)
99. Paez J, Sellers WR. 2003. PI3K/PTEN/AKT pathway. A critical mediator of oncogenic signaling. Cancer Treat. Res. 115:145-67
100. Pinzani M. 2002. PDGF and signal transduction in hepatic stellate cells. Front. Biosci. 7:1720-26
101. Bonacchi A, Romagnani P, Romanelli RG, Efsen E, Annunziato F, et al. 2001. Signal transduction by the chemokine receptor CXCR3: activation of Ras/ERK, Src, and phosphatidylinositol 3-kinase/Akt controls cell migration and proliferation in human vascular pericytes. J. Biol. Chem. 276:9945-54
102. Inagaki Y,Okazaki I. 2007. Emerging insights into Transforming growth factorâSmad signal in hepatic fibrogenesis. Gut 56:284-92
103. Breitkopf K, Godoy P, Ciuclan L, Singer MV, Dooley S. 2006. TGF-â/Smad signaling in the injured liver. Z. Gastroenterol. 44:57-66
104. Chakraborty BC, Mann D. 2010. NF-êB signaling: embracing complexity to achieve translation. J. Hepatology 52:285-91
105. Mann J, Mann DA. 2009. Transcriptional regulation of hepatic stellate cells. Adv. Drug. Deliv. Rev. 61:497-512
106. Tergaonkar V. 2006. NFêB pathway: a good signaling paradigm and therapeutic target. Int. J. Biochem. Cell Biol. 38:1647-53 (Pubitemid 43947652)
107. Oakley F, Mann J, Ruddell RG, Pickford J, Weinmaster G, Mann DA. 2003. Basal expression of IêBáis controlled by the mammalian transcriptional repressor RBP-J (CBF1) and its activator Notch1. J. Biol. Chem. 278:24359-70 (Pubitemid 37548587)
108. Mann J, Oakley F, Akiboye F, Elsharkawy A, Thorne AW, Mann DA. 2007. Regulation of myofibroblast transdifferentiation by DNA methylation and MeCP2: implications for wound healing and fibrogenesis. Cell Death Differ. 14:275-85 (Pubitemid 46092230)
109. Elsharkawy AM,Mann DA. 2007. Nuclear factor-êB and the hepatic inflammation-fibrosis-cancer axis. Hepatology 46:590-97 (Pubitemid 47344795)
110. Shi Z, Wakil AE, Rockey DC. 1997. Strain-specific differences in mouse hepatic wound healing are mediated by divergent T helper cytokine responses. Proc. Natl. Acad. Sci. USA 94:10663-68 (Pubitemid 27430791)
111. Jiang F, Parsons CJ, Stefanovic B. 2006. Gene expression profile of quiescent and activated rat hepatic stellate cells implicates Wnt signaling pathway in activation. J. Hepatol. 45:401-9 (Pubitemid 44142112)
112. Cao Q, Mak KM, Ren C, Lieber CS. 2004. Leptin stimulates tissue inhibitor of metalloproteinase-1 in human hepatic stellate cells: respective roles of the JAK/STAT and JAK-mediated H2O2-dependent MAPK pathways. J. Biol. Chem. 279:4292-304 (Pubitemid 38199017)
113. Gao B. 2005. Cytokines, STATs and liver disease. Cell Mol. Immunol. 2:92-100
114. Jeong WI, Park O, Radaeva S, Gao B. 2006. STAT1 inhibits liver fibrosis in mice by inhibiting stellate cell proliferation and stimulating NK cell cytotoxicity. Hepatology 44:1441-51 (Pubitemid 44953650)
115. AdachiM,Brenner DA. 2008. High molecular weight adiponectin inhibits proliferation of hepatic stellate cells via activation of adenosine monophosphate-activated protein kinase. Hepatology 47:677-85 (Pubitemid 351280736)
116. Teng Y, Zeisberg M, Kalluri R. 2007. Transcriptional regulation of epithelial-mesenchymal transition. J. Clin. Investig. 117:304-6 (Pubitemid 46203957)
117. Eng FJ, Friedman SL. 2001. Transcriptional regulation in hepatic stellate cells. Semin. Liver Dis. 21:385-95 (Pubitemid 32923767)
118. Vincent KJ, Jones E, Arthur MJ, Smart DE, Trim J, et al. 2001. Regulation of E-box DNA binding during in vivo and in vitro activation of rat and human hepatic stellate cells. Gut 49:713-19 (Pubitemid 32989211)
119. Wiercinska E, Wickert L, Denecke B, Said HM, Hamzavi J, et al. 2006. Id1 is a critical mediator in TGF-â-induced transdifferentiation of rat hepatic stellate cells. Hepatology 43:1032-41 (Pubitemid 43738969)
120. Tajima K, Terai S, Takami T, Kawaguchi K, Okita K, Sakaida I. 2007. Importance of inhibitor of DNA binding/differentiation 2 in hepatic stellate cell differentiation and proliferation. Hepatol. Res. 37:647-55 (Pubitemid 47009251)
121. Mann DA, Smart DE. 2002. Transcriptional regulation of hepatic stellate cell activation. Gut 50:891-96 (Pubitemid 34539057)
122. Huang GC, Zhang JS, Tang QQ. 2004. Involvement of C/EBPá gene in in vitro activation of rat hepatic stellate cells. Biochem. Biophys. Res. Commun. 324:1309-18
123. Zhang JW, Tang QQ, Vinson C, Lane MD. 2004. Dominant-negative C/EBP disrupts mitotic clonal expansion and differentiation of 3T3-L1 preadipocytes. Proc. Natl. Acad. Sci. USA 101:43-47 (Pubitemid 38084200)
124. Geier A, Kim SK, Gerloff T, Dietrich CG, Lammert F, et al. 2002. Hepatobiliary organic anion transporters are differentially regulated in acute toxic liver injury induced by carbon tetrachloride. J. Hepatol. 37:198-205 (Pubitemid 34833081)
125. Greenwel P, Dominguez-Rosales JA, Mavi G, Rivas-Estilla AM, Rojkind M. 2000. Hydrogen peroxide: a link between acetaldehyde-elicited á1(I) collagen gene up-regulation and oxidative stress in mouse hepatic stellate cells. Hepatology 31:109-16 (Pubitemid 30033696)
126. Iraburu MJ, Dominguez-Rosales JA, Fontana L, Auster A, Garcia-Trevijano ER, et al. 2000. Tumor necrosis factorádown-regulates expression of theá1(I) collagen gene in rat hepatic stellate cells through a p20C/EBPâ- and C/EBPä-dependent mechanism. Hepatology 31:1086-93 (Pubitemid 30233233)
127. Buck M, Chojkier M. 2007. A ribosomal S-6 kinase-mediated signal to C/EBP-â is critical for the development of liver fibrosis. PLoS ONE 2:e1372
128. Potthoff MJ, Olson EN. 2007. MEF2: a central regulator of diverse developmental programs. Development 134:4131-40
129. Wang X, Tang X, Gong X, Albanis E, Friedman SL, Mao Z. 2004. Regulation of hepatic stellate cell activation and growth by transcription factor myocyte enhancer factor 2. Gastroenterology 127:1174-88 (Pubitemid 39345886)
130. Herrmann J, Borkham-Kamphorst E, Haas U, Van de Leur E, FragaMF, et al. 2006. The expression of CSRP2 encoding the LIM domain protein CRP2 is mediated by TGF-âin smooth muscle and hepatic stellate cells. Biochem. Biophys. Res. Commun. 345:1526-35 (Pubitemid 43817905)
131. Wandzioch E, Kolterud A, Jacobsson M, Friedman SL, Carlsson L. 2004. Lhx2-/- mice develop liver fibrosis. Proc. Natl. Acad. Sci. USA 101:16549-54 (Pubitemid 39557750)
132. Park EY, Shin SM, MaCJ, Kim YC, Kim SG. 2005. Meso-dihydroguaiaretic acid from Machilus thunbergii down-regulates TGF-â1 gene expression in activated hepatic stellate cells via inhibition of AP-1 activity. Planta Med. 71:393-38
133. Chen A, BenoDWA,Davis BH. 1996. Suppression of stellate cell type I collagen gene expression involves AP-2 transmodulation of nuclear factor 1-dependent gene transcription. J. Biol. Chem. 271:25994-98 (Pubitemid 26347436)
134. Anania FA, Potter JJ, Rennie-Tankersley L, Mezey E. 1995. Effects of acetaldehyde on nuclear protein binding to the nuclear factor I consensus sequence in theá2(I) collagen promoter. Hepatology 21:1640-48
135. Bell DM, Leung KK, Wheatley SC, Ng LJ, Zhou S, et al. 1997. SOX9 directly regulates the type-II collagen gene. Nat. Genet. 16:174-78 (Pubitemid 27240616)
136. MillianoMT, Luxon BA. 2005. Rat hepatic stellate cells become retinoid unresponsive during activation. Hepatol. Res. 33:225-33 (Pubitemid 41794211)
137. Kuipers F, Claudel T, Sturm E, Staels B. 2004. The farnesoid X receptor (FXR) as modulator of bile acid metabolism. Rev. Endocr. Metab. Disord. 5:319-26 (Pubitemid 39388749)
138. Fiorucci S, Antonelli E, Rizzo G, Renga B,Mencarelli A, et al. 2004. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology 127:1497-512 (Pubitemid 39457775)
139. Haughton EL, Tucker SJ, Marek CJ, Durward E, Leel V, et al. 2006. Pregnane X receptor activators inhibit human hepatic stellate cell transdifferentiation in vitro. Gastroenterology 131:194-209 (Pubitemid 44015746)
140. Hazra S, Xiong S, Wang J, Rippe RA, Krishna V, et al. 2004. Peroxisome proliferator-activated receptor ãinduces a phenotypic switch from activated to quiescent hepatic stellate cells. J. Biol. Chem. 279:11392-401 (Pubitemid 38401638)
141. Tsukamoto H. 2005. Adipogenic phenotype of hepatic stellate cells. Alcohol. Clin. Exp. Res. 29:132-33S (Pubitemid 43194339)
142. Lin J, Chen A. 2008. Activation of peroxisome proliferator-activated receptor ãby curcumin blocks the signaling pathways for PDGF and EGF in hepatic stellate cells. Lab. Investig. 88:529-40 (Pubitemid 351581455)
143. Xu J, Fu Y, Chen A. 2003. Activation of peroxisome proliferator-activated receptor ãcontributes to the inhibitory effects of curcumin on rat hepatic stellate cell growth. Am. J. Physiol. Gastrointest. Liver Physiol. 285:G20-30 (Pubitemid 36736384)
144. Ohata M, Lin M, Satre M, Tsukamoto H. 1997. Diminished retinoic acid signaling in hepatic stellate cells in cholestatic liver fibrosis. Am. J. Physiol. 272:G589-96
145. Zvibel I, Bar-Zohar D, Kloog Y, Oren R, Reif S. 2008. The effect of Ras inhibition on the proliferation, apoptosis and matrix metalloproteases activity in rat hepatic stellate cells. Dig. Dis. Sci. 53:1048-53 (Pubitemid 351379847)
146. Mann DA, Mann J. 2008. Epigenetic regulation of hepatic stellate cell activation. J. Gastroenterol.Hepatol. 23(Suppl. 1):S108-11 (Pubitemid 351389041)
147. Niki T, Rombouts K, De Bleser P, De Smet K, Rogiers V, et al. 1999. A histone deacetylase inhibitor, trichostatin A, suppresses myofibroblastic differentiation of rat hepatic stellate cells in primary culture. Hepatology 29:858-67 (Pubitemid 29109602)
148. Rombouts K, Knittel T,Machesky L, Braet F,Wielant A, et al. 2002. Actin filament formation, reorganization and migration are impaired in hepatic stellate cells under influence of trichostatin A, a histone deacetylase inhibitor. J. Hepatol. 37:788-96 (Pubitemid 35404218)
149. Kim JS, Shukla SD. 2005. HistoneH3modifications in rat hepatic stellate cells by ethanol. Alcohol Alcohol. 40:367-72 (Pubitemid 41222394)
150. Bala S, Marcos M, Szabo G. 2009. Emerging role of microRNAs in liver diseases. World J. Gastroenterol. 15:5633-40
151. Carthew RW, Sontheimer EJ. 2009. Origins and mechanisms of miRNAs and siRNAs. Cell 136:642-55
152. Winter J, Jung S, Keller S, Gregory RI, Diederichs S. 2009. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat. Cell Biol. 11:228-34 .
153. Guo CJ, Pan Q, Cheng T, Jiang B, Chen GY, Li DG. 2009. Changes in microRNAs associated with hepatic stellate cell activation status identify signaling pathways. FEBS J. 276:5163-76
154. Venugopal SK, Jiang J, Kim TH, Li Y, Wang SS, et al. 2009. Liver fibrosis causes down-regulation of miRNA-150 and miRNA-194 in hepatic stellate cells and their overexpression causes decreased stellate cell activation. Am. J. Physiol. Gastrointest. Liver Physiol. 298:101-6
155. Ji J, Zhang J,Huang G, Qian J, Wang X, Mei S. 2009. Over- expressedmicroRNA-27a and 27b influence fat accumulation and cell proliferation during rat hepatic stellate cell activation. FEBS Lett. 583:759-66
156. Bai X,Wu L, Liang T, Liu Z, Li J, et al. 2008. Overexpression of myocyte enhancer factor 2 and histone hyperacetylation in hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 134:83-91 (Pubitemid 350060688)
157. Gao B, Jeong WI, Tian Z. 2008. Liver: an organ with predominant innate immunity. Hepatology 47:729-36 (Pubitemid 351280741)
158. Szabo G, Mandrekar P, Dolganiuc A. 2007. Innate immune response and hepatic inflammation. Semin. Liver Dis. 27:339-50 (Pubitemid 350071835)
159. Paik YH, Schwabe RF, Bataller R, Russo MP, Jobin C, Brenner DA. 2003. Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology
160. Seki E, De Minicis S, Osterreicher CH, Kluwe J, Osawa Y, et al. 2007. TLR4 enhances TGF-â signaling and hepatic fibrosis. Nat. Med. 13:1324-32 (Pubitemid 350073596)
161. Guo J, Loke J, Zheng F, Hong F, Yea S, et al. 2009. Functional linkage of cirrhosis-predictive single nucleotide polymorphisms of Toll-like receptor 4 to hepatic stellate cell responses. Hepatology 49:960-68
162. Huang H, Shiffman ML, Friedman S, Venkatesh R, Bzowej N, et al. 2007. A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. Hepatology 46:297-306 (Pubitemid 47344763)
163. Watanabe A, Hashmi A, Gomes DA, Town T, Badou A, et al. 2007. Apoptotic hepatocyte DNA inhibits hepatic stellate cell chemotaxis via Toll-like receptor 9. Hepatology 46:1509-18 (Pubitemid 350155533)
164. Gabele E, MuhlbauerM, Dorn C,Weiss TS, FrohM, et al. 2008. Role of TLR9 in hepatic stellate cells and experimental liver fibrosis. Biochem. Biophys. Res. Commun. 376:271-76
165. Marra F. 2002. Chemokines in liver inflammation and fibrosis. Front. Biosci. 7:1899-914
166. Melhem A, Muhanna N, Bishara A, Alvarez CE, Ilan Y, et al. 2006. Anti-fibrotic activity of NK cells in experimental liver injury through killing of activated HSC. J. Hepatol. 45:60-71 (Pubitemid 43850614)
167. Radaeva S, SunR, Jaruga B, Nguyen VT,Tian Z, Gao B. 2006. Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosisinducing ligand-dependent manners. Gastroenterology 130:435-52 (Pubitemid 43202042)
168. Gao B, Radaeva S, Park O. 2009. Liver natural killer and natural killer T cells: immunobiology and emerging roles in liver diseases. J. Leukoc. Biol. 86:513-28
169. Radaeva S, Wang L, Radaev S, Jeong WI, Park O, Gao B. 2007. Retinoic acid signaling sensitizes hepatic stellate cells to NK cell killing via upregulation of NK cell activating ligand RAE1. Am. J. Physiol. Gastrointest. Liver Physiol. 293:G809-16 (Pubitemid 47605936)
170. Notas G, Kisseleva T, Brenner D. 2009. NK and NKT cells in liver injury and fibrosis. Clin. Immunol. 130:16-26
171. Bendelac A, Savage PB, Teyton L. 2007. The biology of NKT cells. Annu. Rev. Immunol. 25:297-336 (Pubitemid 46697911)
172. Park O, Jeong WI, Wang L, Wang H, Lian ZX, et al. 2009. Diverse roles of invariant natural killer T cells in liver injury and fibrosis induced by carbon tetrachloride. Hepatology 49:1683-94
173. Connolly MK, Bedrosian AS,Mallen-St Clair J, Mitchell AP, et al. 2009. In liver fibrosis, dendritic cells govern hepatic inflammation in mice via TNF-á. J. Clin. Investig. 119:3213-25
174. Romagnani S. 2006. Regulation of the T cell response. Clin. Exp. Allergy 36:1357-66 (Pubitemid 44674119)
175. Mehal WZ, Friedman SL. 2007. The role of inflammation and immunity in the pathogenesis of liver fibrosis. In Liver Immunology, ed. ME Gershwin, JM Veirling, MP Manns, pp. 99-109. Totowa, NJ: Humana
176. Novobrantseva TI, Majeau GR, Amatucci A, Kogan S, Brenner I, et al. 2005. Attenuated liver fibrosis in the absence of B cells. J. Clin. Investig. 115:3072-82 (Pubitemid 41567572)
177. Maher JJ. 2001. Interactions between hepatic stellate cells and the immune system. Semin. Liver Dis. 21:417-26 (Pubitemid 32923769)
178. Pinzani M, Abboud HE, Gesualdo L, Abboud SL. 1992. Regulation of macrophage colony-stimulating factor in liver fat-storing cells by peptide growth factors. Am. J. Physiol. 262:C876-81
179. PinzaniM,Carloni V, Marra F, Riccardi D, Laffi G, Gentilini P. 1994. Biosynthesis of platelet-activating factor and its 1O-acyl analogue by liver fat-storing cells. Gastroenterology 106:1301-11
180. Seki E, De Minicis S, Gwak GY, Kluwe J, Inokuchi S, et al. 2009. CCR1 and CCR5 promote hepatic fibrosis in mice. J. Clin. Investig. 119:1858-70
181. Elsharkawy AM,WrightMC, Hay RT, Arthur MJ,Hughes T, et al. 1999. Persistent activation of nuclear factor-B in cultured rat hepatic stellate cells involves the induction of potentially novel Rel-like factors and prolonged changes in the expression of IêB family proteins. Hepatology 30:761-69 (Pubitemid 29409421)
182. Muhanna N, Doron S, Wald O, Horani A, Eid A, et al. 2008. Activation of hepatic stellate cells after phagocytosis of lymphocytes: a novel pathway of fibrogenesis. Hepatology 48:963-77
183. Hellerbrand,Wang SC, Tsukamoto H, Brenner DA, Rippe RA. 1996. Expression of intracellular adhesion molecule 1 by activated hepatic stellate cells. Hepatology 24:670-76 (Pubitemid 26296014)
184. Knittel T, Dinter C, Kobold D, Neubauer K, Mehde M, et al. 1999. Expression and regulation of cell adhesion molecules by hepatic stellate cells (HSC) of rat liver: involvement of HSC in recruitment of inflammatory cells during hepatic tissue repair. Am. J. Pathol. 154:153-67 (Pubitemid 29031623)
185. Tsuchiya A, Kamimura H, Takamura M, Yamagiwa S, Matsuda Y, et al. 2009. Clinicopathological analysis of CD133+ andNCAM+ human hepatic stem/progenitor cells in damaged livers and hepatocellular carcinomas. Hepatol. Res. 39:1080-90
186. Mallet V, Gilgenkrantz H, Serpaggi J, Verkarre V, Vallet-Pichard A, et al. 2008. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann. Intern. Med. 149:399-403
187. Friedman SL, Bansal MB. 2006. Reversal of hepatic fibrosis-fact or fantasy? Hepatology 43:S82-88
188. Ramachandran P, Iredale JP. 2009. Reversibility of liver fibrosis. Ann. Hepatol. 8:283-91
189. HendersonNC, Iredale JP. 2007. Liver fibrosis: cellular mechanisms of progression and resolution. Clin. Sci. 112:265-80 (Pubitemid 46392114)
190. Issa R, Zhou X, Constandinou CM, Fallowfield J, Millward-Sadler H, et al. 2004. Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated withmatrix cross-linking. Gastroenterology 126:1795-808 (Pubitemid 38736345)
191. Iredale JP. 1997. Tissue inhibitors of metalloproteinases in liver fibrosis. Int. J. Biochem. Cell Biol. 29:43-54 (Pubitemid 27096418)
192. McCrudden R, Iredale JP. 2000. Liver fibrosis, the hepatic stellate cell and tissue inhibitors of metalloproteinases. Histol. Histopathol. 15:1159-68
193. Murphy FR, Issa R, Zhou X, Ratnarajah S, Nagase H, et al. 2002. Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase 1 is mediated via effects on matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis. J. Biol. Chem. 277:11069-76 (Pubitemid 34952866)
194. Duffield JS, Forbes SJ, Constandinou CM, Clay S, Partolina M, et al. 2005. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J. Clin. Investig. 115:56-65 (Pubitemid 40385505)
195. Fallowfield JA, Mizuno M, Kendall TJ, Constandinou CM, Benyon RC, et al. 2007. Scar-associated macrophages are a major source of hepatic matrix metalloproteinase 13 and facilitate the resolution of murine hepatic fibrosis. J. Immunol. 178:5288-95 (Pubitemid 46595314)
196. Knittel T, Mehde M, Kobold D, Saile B, Dinter C, Ramadori G. 1999. Expression patterns of matrix metalloproteinases and their inhibitors in parenchymal and nonparenchymal cells of rat liver: regulation by TNF-áand TGF-â1. J. Hepatol. 30:48-60 (Pubitemid 29023652)
197. Godichaud S, Krisa S, Couronne B, Dubuisson L, Merillon JM, et al. 2000. Deactivation of cultured human liver myofibroblasts by trans-resveratrol, a grapevine-derived polyphenol. Hepatology 31:922-31 (Pubitemid 30169940)
198. Popov Y, Schuppan D. 2009. Targeting liver fibrosis: strategies for development and validation of antifibrotic therapies. Hepatology 50:1294-306
199. Novo E, Marra F, Zamara E, Valfre di Bonzo L,Monitillo L, et al. 2006. Overexpression of Bcl-2 by activated human hepatic stellate cells: resistance to apoptosis as a mechanism of progressive hepatic fibrogenesis in humans. Gut 55:1174-82 (Pubitemid 44085687)
200. Watson MR,Wallace K, Gieling RG, Manas DM, Jaffray E, et al. 2008. NF-êB is a critical regulator of the survival of rodent and human hepatic myofibroblasts. J. Hepatol. 48:589-97
201. Fiorucci S, Rizzo G, Antonelli E, Renga B, Mencarelli A, et al. 2005. A FXR-SHP regulatory cascade modulates TIMP-1 andMMPsexpression inHSCsand promotes resolution of liver fibrosis. J. Pharmacol. Exp. Ther. 314:584-95
202. Mallat A, Teixeira-Clerc F, Deveaux V, Lotersztajn S. 2007. Cannabinoid receptors as new targets of antifibrosing strategies during chronic liver diseases. Expert Opin. Ther. Targets 11:403-9 (Pubitemid 46290962)
203. Passino MA, Adams RA, Sikorski SL, Akassoglou K. 2007. Regulation of hepatic stellate cell differentiation by the neurotrophin receptor p75NTR. Science 315:1853-56 (Pubitemid 46580146)
204. Cassiman D, Denef C, Desmet VJ, Roskams T. 2001. Human and rat hepatic stellate cells express neurotrophins and neurotrophin receptors. Hepatology 33:148-58 (Pubitemid 32016897)
205. Trim N, Morgan S, Evans M, Issa R, Fine D, et al. 2000. Hepatic stellate cells express the low affinity nerve growth factor receptor p75 and undergo apoptosis in response to nerve growth factor stimulation. Am. J. Pathol. 156:1235-43 (Pubitemid 30660002)
206. Kim WH, Matsumoto K, Bessho K, Nakamura T. 2005. Growth inhibition and apoptosis in liver myofibroblasts promoted by hepatocyte growth factor leads to resolution from liver cirrhosis. Am. J. Pathol. 166:1017-28 (Pubitemid 40524427)
207. Inagaki Y, Higashi K, KushidaM, Hong YY, Nakao S, et al. 2008. Hepatocyte growth factor suppresses profibrogenic signal transduction via nuclear export of Smad3 with galectin-7. Gastroenterology 134:1180-90 (Pubitemid 351451969)
208. HigashiyamaR, Inagaki Y,HongYY, KushidaM,Nakao S, et al. 2007. Bone marrow-derived cells express matrix metalloproteinases and contribute to regression of liver fibrosis in mice. Hepatology 45:213-22 (Pubitemid 46144381)
209. Marra F, Bertolani C. 2009. Adipokines in liver diseases. Hepatology 50:957-69
210. Ikejima K, Okumura K, Kon K, Takei Y, Sato N. 2007. Role of adipocytokines in hepatic fibrogenesis. J. Gastroenterol. Hepatol. 22(Suppl. 1):S87-92 (Pubitemid 46849004)
211. Qamar A, Sheikh SZ, Masud A, Jhandier MN, Inayat IB, et al. 2006. In vitro and in vivo protection of stellate cells from apoptosis by leptin. Dig. Dis. Sci. 1697-705
212. Saxena NK,Titus MA,DingX, Floyd J, Srinivasan S, et al. 2004. Leptin as a novel profibrogenic cytokine in hepatic stellate cells:mitogenesis and inhibition of apoptosis mediated by extracellular regulated kinase (ERK) and Akt phosphorylation. FASEB J. 18:1612-14 (Pubitemid 39561650)
213. Gieling RG, Burt AD, Mann DA. 2008. Fibrosis and cirrhosis reversibility-molecular mechanisms. Clin. Liver Dis. 12:915-37, xi
214. Krizhanovsky V, Yon M, Dickins RA, Hearn S, Simon J, et al. 2008. Senescence of activated stellate cells limits liver fibrosis. Cell 134:657-67
215. Schrader J, Fallowfield J, Iredale JP. 2009. Senescence of activated stellate cells: not just early retirement. Hepatology 49:1045-47
216. Millward-Sadler GH,Wright R, ArthurMJP. 1992. Wright's Liver and Biliary Disease, Vol. 2: Pathophysiology, Diagnosis, and Management. New York: Saunders. 3rd ed.
217. Guo J. 2007. Hepatic fibrogenesis. Semin. Liver Dis. 27:413-26 (Pubitemid 350071841)